Highly Sensitive Virome Capture Sequencing Technique VirCapSeq-VERT Identifies Partial Noncoding Sequences but no Active Viral Infection in Cutaneous T-Cell Lymphoma

TO THE EDITOR

The potential role of viruses as onco-genic triggers in cutaneous T-cell lymphoma (CTCL) pathogenesis is a subject of ongoing investigation. CTCL occurs with an increased incidence in immunosuppressed patients (Nikolau et al., 2015; Pomerantz et al., 2010; Wilkins et al., 2006). Spectratoryping studies have shown depleted T-cell receptor diversity in CTCL patients similar to that seen in patients with advanced HIV, and Ingenuity Pathway Analysis (Qiagen, Hilden, Germany) shows increased expression of genes critical to host viral response (Yawalkar et al., 2003). However, no consistent association between a viral pathogen and CTCL has been established (Mirvish et al., 2013).

The development of high-throughput sequencing (HTS) has provided powerful new tools for pathogen discovery, yet HTS studies have not identified viral sequences in CTCL (Dereure et al., 2015). One explanation for failure is that viral burden in samples may be below the threshold for detection in complex backgrounds of host nucleic acid. To address this possibility, we used a positive selection method for HTS with enhanced sensitivity (Briese et al., 2015).

The Virome Capture Sequencing Platform for Vertebrate Viruses (VirCapSeq-VERT; Roche, Pleasanton, CA) is a positive-selection probe-based method that targets all 207 known vertebrate viruses, allowing for a 100- to 10,000-fold increase in the number of viral targets. VirCapSeq-VERT Analysis of CTCL

Abbreviations: contig, contiguous sequence; CTCL, cutaneous T-cell lymphoma; HERV, human endogenous retrovirus; HHV, human herpesvirus; HTLV-1, human T-lymphotropic virus-1; HTS, high-throughput sequencing; NCBI, National Center for Biotechnology Information; TNA, total nucleic acid; VirCapSeq-VERT, virome capture sequencing of vertebrate viruses

Accepted manuscript published online 7 February 2018; corrected proof published online 14 March 2018
© 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
reads over traditional HTS, a degree of sensitivity comparable to targeted real-time PCR. Over 90% of genome recovery can be achieved with only 100 viral copies in 50 ng of whole-blood nucleic acid. Superior to real-time PCR, however, VirCapSeq-VERT can detect viruses that differ from known sequences by 40% (Briese et al., 2015).

We used VirCapSeq-VERT to search for viral sequences in mononuclear cells derived from the peripheral blood of leukemic CTCL patients with Sézary syndrome. In total, 27 million paired-end reads were generated using Illumina MiSeq, with an average of 2.25 million paired-end reads per sample. An average of 11% of the reads were removed after filtration; 74% of the reads were removed after host subtraction. Overall, 49,349 sequences showed partial homology to 23 unique viral species including human endogenous retroviruses (HERVs) H and K, human herpesvirus (HHV) 4 and 5, HIV, human T-lymphotropic virus-1 (HTLV-1), Lassa virus, Luna virus, bovine viral diarrhea virus, and Ngari virus (Table 1).

Bovine viral diarrhea virus sequences are common in bovine serum products used in sample collection and thus were excluded from further analysis. HERV-H/ env62 and HERV-H/env59 sequences were present in 2 of 6 and 3 of 6 samples, respectively, matching to a proviral copy. The HHV-4 and HHV-5 sequences were present in 1 of 6 samples tested; 36 reads matched to the partial HHV genome. HIV-1 sequences were present in 1 of 6 samples, partially matching to a nonfunctional pol protein gene. Short sequences with partial homology to Lassa, Ngari, and Luna viruses were present in 4 of 6, 5 of 6, and 6 of 6 samples, respectively. Detailed analysis indicated that these sequences were 100% homologous to human genomic sequences (accession number KF478765.1 for Lassa, KJ168491.1 for Ngari, and AB972431.1 and KX121618.1 for Luna). Thus, the reference sequences likely represent misannotations. HERV-K and HTLV-1 sequences were present in 6 of 6 samples. The HERV-K sequences comprised partially coding proviral sequences, and the HTLV-1 sequences matched to defective proviral sequences, both showing high similarity to the host genome.

We conducted this study using VirCapSeq-VERT to search for viral sequences in patients with CTCL. VirCapSeq-VERT’s ability to detect all known vertebrate viruses offers the most sensitive detection methods compared with conventional HTS and targeted reverse transcription PCR. No substantive coding sequences for viral pathogens or unknown viruses, or evidence for active infection, were obtained. All six Sézary syndrome samples expressed partial, noncoding sequences for HERV-K and HTLV-1, but these sequences had low read counts and contiguous sequence (contig) depths, and were thus insufficient to be considered as positive results. Nevertheless, their presence is of interest, because both viruses have been previously implicated in CTCL. HTLV-1’s role in CTCL has been debated at length (Mirvish et al., 2013). HERVs are expressed in all human tissues but have been implicated in cancer pathogenesis, and increased expression of HERVs has been seen in CTCL patients (Fava et al., 2016; Maliniemi et al., 2013). Sequencing of healthy control patient samples with matched demographics was not available for this pilot study for direct comparison, but further investigation may elucidate the significance of these partial noncoding sequences and whether these viruses could play a genuine role in CTCL pathogenesis.

Six Sézary syndrome patients diagnosed according to the World Health Organization-European Organization for Research and Treatment of Cancer criteria were enrolled after receiving Columbia University Medical Center Institutional Review Board approval. Written informed patient consent was obtained from all patients (5 women, 1 man; age range = 58–82 years; 3 Caucasian, 2 Hispanic, and 1 African American).

Whole blood from each patient was collected. Peripheral blood mononuclear cells were isolated via density gradient centrifugation (Ficoll-Plaque; Millipore Sigma, St. Louis, MO), and plasma was isolated via centrifugation.

### Table 1. Potential viral species counts from MegaBLAST

<table>
<thead>
<tr>
<th>Viral Species</th>
<th>Sample ID</th>
<th>Maximum Sequence Length (nt)²</th>
<th>Maximum Contig Depth (Number of Reads)²</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVDV</td>
<td>1 2 3 4 5 6</td>
<td>1,837</td>
<td>108</td>
<td>Library preparation artifact</td>
</tr>
<tr>
<td>HERV-H/env59</td>
<td>8</td>
<td>145</td>
<td>2</td>
<td>Proviral sequences</td>
</tr>
<tr>
<td>HERV-H/env62</td>
<td>15 8</td>
<td>145</td>
<td>2</td>
<td>Proviral sequences</td>
</tr>
<tr>
<td>HERV-K</td>
<td>60 19 96 41 45 52</td>
<td>875</td>
<td>14</td>
<td>Low abundance/prevalence</td>
</tr>
<tr>
<td>HHV-4</td>
<td>24</td>
<td>145</td>
<td>3</td>
<td>Proviral sequences</td>
</tr>
<tr>
<td>HHV-5</td>
<td>12</td>
<td>145</td>
<td>2</td>
<td>Proviral sequences</td>
</tr>
<tr>
<td>HIV-1</td>
<td>10</td>
<td>84</td>
<td>4</td>
<td>Nonfunctional pol polymerase protein gene</td>
</tr>
<tr>
<td>HTLV-1</td>
<td>15 32 8 28 69 22</td>
<td>145</td>
<td>2</td>
<td>Proviral sequences</td>
</tr>
<tr>
<td>Lassa virus</td>
<td>11 8</td>
<td>145</td>
<td>1</td>
<td>Likely misannotation</td>
</tr>
<tr>
<td>Luna virus</td>
<td>3,912 3,804 3,673 111 372 3,533</td>
<td>432</td>
<td>26</td>
<td>Likely misannotation</td>
</tr>
<tr>
<td>Ngari virus</td>
<td>33 20 26</td>
<td>145</td>
<td>2</td>
<td>Likely misannotation</td>
</tr>
</tbody>
</table>

Abbreviations: BVDV, bovine viral diarrhea virus; contig, contiguous sequence; HERV, human endogenous retrovirus; HHV, human herpes virus; HTLV-1, human lymphotropic virus 1; ID, identification; nt, nucleotide.

²Maximum sequence length and contig depth are in sample 1.
Total nucleic acid (TNA) was extracted from the plasma and peripheral blood mononuclear cells using NucliSENS easyMAG (BioMérieux, Marcy l’Etoile, France). TNAs were processed according to Center for Infection and Immunity standard operating procedures for VirCapSeq-VERT. Briefly, the VirCapSeq-VERT probe library was added to the TNAs. Positively selected and enriched sequences underwent PCR amplification and sequencing using the Illumina (San Diego, CA) MiSeq platform. The 150-nucleotide reads were then mapped to reference genomes identified from BLAST using Geneious, version 6.0.6 ( Biomatters INC, Newark, NJ). The sequence data supporting the results of this article are available in NCBI under accession number PRJNA415045 with biosample accession numbers SAMN07812478–83.

ORCIDs
Mary Elizabeth Anderson: http://orcid.org/0000-0003-1364-1248
Christina Chung Patrone: http://orcid.org/0000-0001-8906-7460

CONFLICT OF INTEREST
The authors state no conflict of interest.

ACKNOWLEDGMENTS
We thank Lisa Keller and Saky Yakas for their philanthropic support of cutaneous lymphoma research at Columbia University.

Mary E. Anderson1,4, Dorottya Nagy-Szakal2,4, Komal Jain2, Christina C. Patrone1, Mark G. Frattini3, W. Ian Lipkin2 and Larisa J. Geskin1,*
1 Department of Dermatology, Columbia University Medical Center, New York, New York, USA; 2 Center for Infection and Immunity, Mailman School of Public Health, Columbia University Medical Center, New York, New York, USA; and 3 Department of Medicine, Columbia University Medical Center, New York, New York, USA
*These authors contributed equally to this work.
Corresponding author e-mail: ljg2145@cumc.columbia.edu

REFERENCES